Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Primary Clinic (Direct GLP) vs Tell Her Doc

Primary Clinic (Direct GLP)
Graded #145

Higher grade

vs+11.5
Tell Her Doc
Graded #404

Lower grade

The verdict

Primary Clinic (Direct GLP) takes it — 68.7/100 to 57.2/100.

Primary Clinic (Direct GLP) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePrimary Clinic (Direct GLP) +51
78
27
Dose & formulationTell Her Doc +9
54
63
Clinical oversightTell Her Doc +1
75
76
Labs & monitoringPrimary Clinic (Direct GLP) +24
76
52
FulfillmentTell Her Doc +10
73
83
Contract termsTell Her Doc +20
41
61
Primary Clinic (Direct GLP) · left barTell Her Doc · right bar

The numbers

MetricPrimary Clinic (Direct GLP)Tell Her Doc
WeighScore68.7/10057.2/100
GradeCC
Scorecard rank#145#404
Semaglutide$65/mo (0.25 mg dose, promotional rate, compounded)$269/mo (microdose tier, plus a separate fee, compounded)
Tirzepatide$110/mo (2.5 mg dose, promotional rate, compounded)Not disclosed
Coverage10 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes

Strengths

  • Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
  • GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
  • Routine labs and thousands of medications included in membership — no surprise bills
  • Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide

Where it loses points

  • 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
  • Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
  • 503A pharmacy partners not named
  • LegitScript certification not mentioned on the site
  • Medical director and corporate legal entity not disclosed
Tell Her Doc

Graded #404 · C

Strengths

  • Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
  • Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
  • No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
  • Serves patients in all 50 states via a private online consultation

Where it loses points

  • 'All sales are final' — no refunds once medication has left the pharmacy
  • Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
  • References LegitScript but without an independently verifiable seal — we couldn't confirm certification
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard